| Nov 13 |
MIRA Continues Solid Financial Management
|
| Oct 29 |
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
|
| Oct 28 |
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
|
| Oct 28 |
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
|
| Oct 27 |
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024
|
| Oct 21 |
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
|
| Oct 21 |
MIRA Continues to Post Outstanding Test Results
|
| Sep 27 |
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
|
| Sep 18 |
MIRA Makes Impressive Progress
|
| Sep 18 |
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
|
